Schering-Plough Reports Financial Results for 2009 Seco...(As Adjust- Related Specifi...)

Date:7/21/2009

As Adjust- Related Specified Reconciled Reported ments Items Items (1) -------- ----- ----- ----- --- Net sales $4,647 $- $- $- $4,647 Cost of sales 1,620 (131) (5) - 1,484 Selling, general and administrative 1,626 (1) - - 1,625 Research and development 863 (3) - - 860 Other expense/ (income), net 106 - - - 106 Special, merger and acquisition-related charges 29 - (29) - - Equity income (370) - - - (370) ----- - - - ----- Income before income taxes 773 135 34 - 942 Income tax expense/(benefit) 102 (27) (6) - 135 --- ---- --- - --- Net income $671 $108 $28 $- $807 ---- ---- === -- ---- Preferred stock dividends 38 - - - 38 -- - - - -- Net income available To common shareholders $633 $108 $28 $- $769 ==== ==== === == ==== Diluted earnings per common share (2) $0.38 $0.46 ===== ===== Average shares outstanding
'/>"/>

SOURCE Schering-Plough Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma